Related Experiment Videos
The in vitro effect of Pidotimod on some immune functions in cancer patients
M Di Renzo1, A L Pasqui, F Bruni
1Department of Clinical Immunology, University of Siena, Italy.
Abstract:
There are several reports concerning an impairment of cellular immune response in patients affected by malignant disease. The aim of this study was to evaluate the in vitro effect of Pidotimod, a synthetic biological response modifier, on some immune functions in 14 cancer patients. In particular, we showed that these subjects had a significantly reduced peripheral blood mononuclear cell (PBMC) proliferation both in response to PHA and to Con A in comparison with a group of healthy subjects. Besides, they showed a significantly reduced PBMC IL2 production, which was evaluated both through an ELISA method and a biological assay. The in vitro addition of increasing concentrations of Pidotimod (10, 25 and 50 ug/ml) was able to enhance PBMC proliferation and IL2 production significantly. However, in spite of the addition of Pidotimod, both immune functions in our neoplastic patients did not reach normal values.
Insights
This study investigated Pidotimod
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Cancer patients often exhibit impaired cellular immune responses.
- Reduced peripheral blood mononuclear cell (PBMC) proliferation and IL2 production are observed in cancer patients.
- Evaluating immune function is crucial for understanding cancer patient health.
Purpose of the Study:
- To assess the in vitro impact of Pidotimod on immune functions in cancer patients.
- To determine if Pidotimod can restore cellular immune response in neoplastic disease.
- To analyze Pidotimod's effect on PBMC proliferation and IL2 production.
Main Methods:
- In vitro study involving 14 cancer patients.
- Measured peripheral blood mononuclear cell (PBMC) proliferation in response to PHA and Con A.
- Assessed Interleukin-2 (IL2) production using ELISA and biological assays.
- Administered increasing concentrations of Pidotimod (10, 25, 50 ug/ml).
Main Results:
- Cancer patients showed significantly reduced PBMC proliferation and IL2 production compared to healthy subjects.
- In vitro Pidotimod enhanced PBMC proliferation and IL2 production in cancer patients.
- Despite Pidotimod's enhancement, immune functions did not fully normalize.
Conclusions:
- Pidotimod demonstrates potential in enhancing cellular immune responses in cancer patients.
- Further research is needed to achieve complete restoration of immune function.
- Pidotimod may be a valuable therapeutic agent for modulating immune response in malignancy.